ArticleOncotarget2017
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
Hong Ren et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this paperpooled itcites it